Table 1.

Proportion of patients developing IgG antibodies and neutralizing capacity against SARS-CoV-2 after infection and vaccination

Infected			Vaccinated
	N	N (%)	N	N (%)	p-value
IgG antibodies against RBD
Overall	69	65 (94.2)	326	260 (79.7)	0.004
KTR	22	19 (86.4)	129	72 (55.8)	0.007
HD	24	23 (95.8)	85	76 (89.4)	0.45
Control	23	23 (100.0)	112	112 (100.0)	*
IgG antibodies against S1S2
Overall	69	65 (94.2)	326	248 (76.1)	0.001
KTR	22	19 (86.4)	129	60 (46.5)	0.001
HD	24	23 (95.8)	85	76 (89.4)	0.45
Control	23	23 (100.0)	112	112 (100.0)	-
IgG antibodies against NP
Overall	69	66 (95.7)		NA
KTR	22	20 (90.9)		NA
HD	24	23 (95.8)		NA
Control	23	23 (100.0)		NA
Neutralizing capacity
Overall	69	62 (89.9)	152	145 (95.4)	0.14
KTR	22	20 (90.9)	21	17 (80.9)	0.41
HD	24	23 (95.8)	24	21 (87.5)	0.61
Control	23	19 (82.6)	107	107 (100.0)	0.001

Table showing the proportion of patients who developed IgG antibodies against RBD, the S1S2 domain of SARS-CoV-2, NP and neutralizing capacity. Numbers highlighted in bold indicate statistical significance. KTR Kidney transplant recipients; HD hemodialysis; RBD receptor binding domain, NP nucleocapsid protein. *no variation